false
0001445815
0001445815
2026-08-11
2026-08-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 11, 2026
BIOXYTRAN,
INC.
(Exact
Name of Registrant as Specified in Charter)
| Nevada |
|
001-35027 |
|
26-2797630 |
| (State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
Number) |
| 75
Second Ave, Suite 605, Needham, MA |
|
02494 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code 617-454-1199
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| |
|
|
|
|
| Common
Stock, par value $0.001 |
|
BIXT |
|
OTCQB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events
On
August 11, 2026, the Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title:
Bioxytran
Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID,
a Novel Galectin Antagonist Designed with Artificial Intelligence
Item
9.01 Financial Statements and Exhibits.
Exhibit
Number |
|
Description |
| |
|
|
| 99.1* |
|
Press Release dated August 11, 2026, entitled “Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence”. |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
| * |
Filed as an exhibit hereto. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
BIOXYTRAN,
INC. |
| |
|
|
| |
By: |
/s/
David Platt, Ph.D. |
| |
|
David
Platt, Ph.D., its Chief Executive Officer |
| |
|
|
| Date
August 11, 2026 |
|
EXHIBIT
99.1
Bioxytran
Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID,
a Novel Galectin Antagonist Designed with Artificial Intelligence
Once-weekly
intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported
during treatment
BOSTON,
MA – August 11, 2026 – Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering galectin-targeting
carbohydrate therapeutics, today announced positive clinical results from the first patient treated with PLICID, an investigational galectin
antagonist for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The
patient, who had been living with CIDP—a rare neurological disorder characterized by progressive weakness and impaired sensory
function due to immune-mediated damage to peripheral nerves—received once-weekly intravenous injections of PLICID. Following treatment,
the patient was reported to have regained use of their fingers and the ability to walk several miles, representing an encouraging functional
improvement in this individual patient. No adverse side effects were reported throughout the treatment course.
PLICID
is a complex carbohydrate drug designed through Bioxytran’s proprietary Artificial Super Intelligence (ASI)-driven drug design
platform, developed with researchers at the University of Minnesota Department of Chemistry. The ASI platform interprets nuclear magnetic
resonance (NMR) spectroscopy data to calculate and construct novel carbohydrate structures that precisely target specific galectins implicated
in disease pathology. The platform uses NMR spectroscopy data and computational methods to support the design and evaluation of carbohydrate
structures targeting specific galectins implicated in disease pathology.
Bioxytran
has worked with Dr. Kevin Mayo, a recognized expert in biomolecular structure and NMR spectroscopy at the University of Minnesota, on
biochemical research relating to polysaccharide and oligosaccharide interactions with biologically relevant targets. Bioxytran’s
galectin antagonist platform leverages linear complex carbohydrate chemical structures to block galectins—proteins implicated in
inflammatory, fibrotic, and malignant diseases.
“We
are encouraged by the clinical response observed in this first CIDP patient treated with PLICID,” said David Platt, PhD, Chief
Executive Officer of Bioxytran. “Regaining functional use of the fingers and the ability to walk miles represents a meaningful
improvement in quality of life. The absence of reported adverse events during treatment is also encouraging. This case supports further
evaluation of the potential for our ASI-designed galectin antagonists to address serious neurological and inflammatory conditions where
current treatment options remain limited.”
Seeing
this patient experience meaningful improvement in motor function, including improved finger function and walking ability, is encouraging,”
said Dr. Leslie Ajayi, Chief Medical Officer and Chief of the Medical Advisory Board at Bioxytran. “This initial experience supports
further investigation of PLICID and our galectin-targeting approach in CIDP. Our galectin antagonist approach is rooted in a deep understanding
of disease pathogenesis, and this initial response in CIDP validates the potential of PLICID to address the underlying inflammatory drivers
of this debilitating condition.”
While
the Company recognizes that observations from a single patient are not sufficient to establish the safety or efficacy of PLICID, the
initial clinical observations are encouraging and support further investigation in a larger, appropriately designed clinical study. The
observations are indicative of the transformative potential of ASI-designed galectin-targeting therapeutics. Bioxytran intends to pursue
further clinical evaluation of PLICID in a larger patient population to further evaluate PLICID’s therapeutic profile.
CIDP
is a rare, acquired immune-mediated neuropathy affecting the peripheral nervous system. Current standard-of-care treatments include intravenous
immunoglobulin, corticosteroids, and plasma exchange. Bioxytran is investigating a galectin-targeting approach with a proposed mechanism
of action distinct from existing CIDP therapies.
Bioxytran
continues to advance its pipeline of galectin antagonist therapies across multiple indications, leveraging its ASI-powered carbohydrate
design platform. The Company is a clinical-stage pharmaceutical company developing platform technologies in Glycovirology, hypoxia, and
degenerative diseases using carbohydrate drug design.
About
Bioxytran, Inc.
Bioxytran,
Inc. (OTCQB: BIXT) is a clinical-stage biotechnology company developing innovative therapies for viral diseases, inflammatory conditions,
and cancer metastasis. The Company’s proprietary Artificial Super Intelligence-driven carbohydrate design platform, developed in
collaboration with researchers at the University of Minnesota Department of Chemistry, enables the rational design of complex carbohydrate
therapeutics targeting galectins and related biological pathways.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, among other things, statements regarding the potential safety, efficacy, therapeutic benefits, mechanism of action,
and future development of PLICID; the significance of observations from the first CIDP patient treated with PLICID; the potential for
such observations to be replicated in additional patients or future clinical studies; the Company’s plans to pursue further clinical
evaluation of PLICID in CIDP and other indications; the potential of the Company’s galectin-targeting therapeutic approach; and
the capabilities and potential applications of the Company’s carbohydrate drug design platform.
Forward-looking
statements are based on management’s current expectations, assumptions, and beliefs and involve risks and uncertainties that could
cause actual results to differ materially from those expressed or implied by such statements. In particular, observations from a single
patient cannot establish the safety or efficacy of PLICID and may not be indicative of results in other patients or in future clinical
studies. There can be no assurance that PLICID will demonstrate safety or efficacy in larger patient populations, successfully complete
clinical development, receive regulatory approval, or be commercially successful.
Additional
risks and uncertainties include those described in Bioxytran’s filings with the U.S. Securities and Exchange Commission. Readers
are cautioned not to place undue reliance on these forward-looking statements. Bioxytran undertakes no obligation to update or revise
any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.
